Amvia Sky DR-T, Amvia Sky SR-T; Amvia Edge DR-T, Amvia Edge SR-T; Solvia Rise DR-T, Solvia Rise SR-T; Amvia Sky HF-T QP,
Biotronik, Inc. · Decision date Oct 28, 2026
What did the FDA decide?
FDA posted a 30-day notice for supplement S300 to PMA P950037, dated 2026-10-28, with decision OK30. The stated purpose is to implement updates to the final acceptance testing workflow for the Amvia/Solvia family of pacemakers and CRT-Ps. The supplement reason is recorded as a process change involving manufacturer, sterilizer, packager, or supplier.
The affected devices include Amvia Sky DR-T, Amvia Sky SR-T, Amvia Edge DR-T, Amvia Edge SR-T, Solvia Rise DR-T, Solvia Rise SR-T, and Amvia Sky HF-T QP. The source statement does not describe the specific acceptance-testing changes, the manufacturing site, or any effect on device labeling or performance. A supplement of this type is not a new approval of the whole system.
FDA approval order statement
to implement updates to the final acceptance testing workflow for the Amvia/Solvia family of pacemakers and CRT-Ps
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 28, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P950037/S300
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik, Inc.
- Product code
- DXY
- Decision code
- OK30
- Decision date
- Oct 28, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: implantable pacemaker Pulse-generator.
- Applicant
- Biotronik, Inc.
- Product code
- DXY
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P950037. Subsequent supplements may change the device or its indications.
FDA decision timeline
P950037 · Original PMA
DROMOS DR/DR-A AND DROMOS SR/SR-B CARDIAC PACING SYSTEMS
P950037/S291 · Related supplement
PSW 2601.U, NEO 2601.U, Amvia Sky HF-T QP, Amvia Sky HF-T, Amvia Edge HF-T QP, Amvia Sky DR-T, Amvia Sky SR-T, Amvia Edg
P950037/S279 · Related supplement
Edora 8 DR-T 407145, Evity 8 DR-T 407146, Enitra 8 DR-T 407147, Enticos 8 DR-T 407148, Evity 6 DR-T 407149, Enitra 6 DR-
P950037/S300 received
Application receipt date recorded by FDA.
P950037/S296 · Related supplement
Edora 8 DR-T 407145; Evity 8 DR-T 407146; Enitra 8 DR-T 407147; Enticos 8 DR-T 407148; Evity 6 DR-T 407149; Enitra 6 DR-
P950037/S298 · Related supplement
Edora 8 DR-T, Evity 8 DR-T, Enitra 8 DR-T, Evity 6 DR-T, Enitra 6 DR-T, Edora 8 DR, Enitra 6 DR, Enticos 4 DR, Enticos
P950037/S289 · Related supplement
BIOexpress
P950037/S299 · Related supplement
Edora 8 DR-T, Evity 8 DR-T, Enitra 8 DR-T, Enticos 8 DR-T, Evity 6 DR-T, Enitra 6 DR-T, Edora 8 DR, Enitra 6 DR, Edora 8
P950037/S300 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P950037. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P950037
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA approval | Oct 11, 1996 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 17, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
BIOexpressP950037/S289 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6024 Jean Rd., Lake Oswego, OR, 97035
Sources and methodology
- Original FDA record: P950037/S300
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




